

# Steven Goossens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5121316/publications.pdf>

Version: 2024-02-01

56  
papers

2,408  
citations

279778

23  
h-index

214788

47  
g-index

57  
all docs

57  
docs citations

57  
times ranked

5057  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy. <i>Cancers</i> , 2022, 14, 902.	3.7	39
2	Myb drives B-cell neoplasms and myeloid malignancies in vivo. <i>Blood Advances</i> , 2022, 6, 2987-2991.	5.2	1
3	MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus. <i>JCI Insight</i> , 2022, 7, .	5.0	7
4	Distinct Transcriptional Programs in Ascitic and Solid Cancer Cells Induce Different Responses to Chemotherapy in High-Grade Serous Ovarian Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1532-1547.	3.4	2
5	RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition. <i>Science Advances</i> , 2022, 8, .	10.3	15
6	RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	20
7	The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL. <i>Blood Advances</i> , 2021, 5, 1963-1976.	5.2	9
8	Pancreas morphogenesis and homeostasis depends on tightly regulated Zeb1 levels in epithelial cells. <i>Cell Death Discovery</i> , 2021, 7, 138.	4.7	3
9	Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	12
10	Interplay between the EMT transcription factors ZEB1 and ZEB2 regulates hematopoietic stem and progenitor cell differentiation and hematopoietic lineage fidelity. <i>PLoS Biology</i> , 2021, 19, e3001394.	5.6	18
11	Unlike its Paralog LEDGF/p75, HRP-2 Is Dispensable for MLL-R Leukemogenesis but Important for Leukemic Cell Survival. <i>Cells</i> , 2021, 10, 192.	4.1	5
12	Direct and indirect anti-leukemic properties of Activity-on-Target interferons for the treatment of T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2021, , .	3.5	2
13	Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. <i>Blood</i> , 2020, 135, 1685-1695.	1.4	28
14	The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1. <i>Blood</i> , 2020, 136, 957-973.	1.4	35
15	Zeb2 drives invasive and microbiota-dependent colon carcinoma. <i>Nature Cancer</i> , 2020, 1, 620-634.	13.2	29
16	The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype. <i>Cancer Research</i> , 2020, 80, 2983-2995.	0.9	51
17	Ageing of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia. <i>Blood Cancer Discovery</i> , 2020, 1, 274-289.	5.0	21
18	Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. <i>Haematologica</i> , 2019, 104, e17-e20.	3.5	18

#	ARTICLE	IF	CITATIONS
19	Genetic characterization and therapeutic targeting of <i>MYC</i> -rearranged T cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2019, 185, 169-174.	2.5	9
20	Targeting steroid resistance in T-cell acute lymphoblastic leukemia. <i>Blood Reviews</i> , 2019, 38, 100591.	5.7	20
21	Novel strategy for rapid functional in vivo validation of oncogenic drivers in haematological malignancies. <i>Scientific Reports</i> , 2019, 9, 10577.	3.3	5
22	ZEB2 in T-cells and T-ALL. <i>Advances in Biological Regulation</i> , 2019, 74, 100639.	2.3	7
23	ZEB2 and LMO2 drive immature T-cell lymphoblastic leukemia via distinct oncogenic mechanisms. <i>Haematologica</i> , 2019, 104, 1608-1616.	3.5	22
24	USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia. <i>Clinical Cancer Research</i> , 2019, 25, 222-239.	7.0	66
25	LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis. <i>Blood</i> , 2018, 131, blood-2017-05-786962.	1.4	32
26	A Novel <i>Asparaginase</i> with low <i>Glutaminase</i> Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias <i>In Vivo</i> . <i>Cancer Research</i> , 2018, 78, 1549-1560.	0.9	67
27	A knock-in/knock-out mouse model of HSPB8-associated distal hereditary motor neuropathy and myopathy reveals toxic gain-of-function of mutant Hspb8. <i>Acta Neuropathologica</i> , 2018, 135, 131-148.	7.7	58
28	ZEB Proteins in Leukemia: Friends, Foes, or Friendly Foes?. <i>HemaSphere</i> , 2018, 2, e43.	2.7	23
29	ZEB2 stably represses RAB25 expression through epigenetic regulation by SIRT1 and DNMTs during epithelial-to-mesenchymal transition. <i>Epigenetics and Chromatin</i> , 2018, 11, 70.	3.9	15
30	Expressed repetitive elements are broadly applicable reference targets for normalization of reverse transcription-qPCR data in mice. <i>Scientific Reports</i> , 2018, 8, 7642.	3.3	10
31	Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, 981-990.	1.4	17
32	Novel oncogenic noncoding mutations in T-ALL. <i>Blood</i> , 2017, 129, 3140-3142.	1.4	5
33	Epithelial-to-Mesenchymal Transition: Epigenetic Reprogramming Driving Cellular Plasticity. <i>Trends in Genetics</i> , 2017, 33, 943-959.	6.7	205
34	Structure-function Studies in Mouse Embryonic Stem Cells Using Recombinase-mediated Cassette Exchange. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	4
35	EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 584-591.	7.4	214
36	Zeb2 Regulates Cell Fate at the Exit from Epiblast State in Mouse Embryonic Stem Cells. <i>Stem Cells</i> , 2017, 35, 611-625.	3.2	41

#	ARTICLE	IF	CITATIONS
37	p120 Catenin-Mediated Stabilization of E-Cadherin Is Essential for Primitive Endoderm Specification. <i>PLoS Genetics</i> , 2016, 12, e1006243.	3.5	26
38	Characterization of New Transgenic Mouse Models for Two Charcot-Marie-Tooth-Causing HspB1 Mutations using the Rosa26 Locus. <i>Journal of Neuromuscular Diseases</i> , 2016, 3, 183-200.	2.6	9
39	LIN28B is over-expressed in specific subtypes of pediatric leukemia and regulates lncRNA H19. <i>Haematologica</i> , 2016, 101, e240-e244.	3.5	18
40	Overcoming Steroid Resistance in T Cell Acute Lymphoblastic Leukemia. <i>PLoS Medicine</i> , 2016, 13, e1002208.	8.4	16
41	Strategies to Rescue the Consequences of Inducible Arginase-1 Deficiency in Mice. <i>PLoS ONE</i> , 2015, 10, e0125967.	2.5	12
42	ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. <i>Nature Communications</i> , 2015, 6, 5794.	12.8	75
43	Novel biological insights in T-cell acute lymphoblastic leukemia. <i>Experimental Hematology</i> , 2015, 43, 625-639.	0.4	97
44	Terminal NK cell maturation is controlled by concerted actions of T-bet and Zeb2 and is essential for melanoma rejection. <i>Journal of Experimental Medicine</i> , 2015, 212, 2015-2025.	8.5	151
45	Transcriptional repressor ZEB2 promotes terminal differentiation of CD8+ effector and memory T cell populations during infection. <i>Journal of Experimental Medicine</i> , 2015, 212, 2027-2039.	8.5	206
46	Alpha-Catenins Control Cardiomyocyte Proliferation by Regulating Yap Activity. <i>Circulation Research</i> , 2015, 116, 70-79.	4.5	106
47	Controlling Pre-leukemic Thymocyte Self-Renewal. <i>PLoS Genetics</i> , 2014, 10, e1004881.	3.5	8
48	MicroRNA-128-3p is a novel oncomiR targeting PHF6 in T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2014, 99, 1326-1333.	3.5	55
49	Loss of autocrine endothelial-derived VEGF significantly reduces hemangiosarcoma development in conditional p53-deficient mice. <i>Cell Cycle</i> , 2014, 13, 1501-1507.	2.6	10
50	ZEB2-transgene expression in the epidermis compromises the integrity of the epidermal barrier through the repression of different tight junction proteins. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 3599-609.	5.4	20
51	ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2014, 124, 3738-3747.	1.4	198
52	Efficient ROSA26-Based Conditional and/or Inducible Transgenesis Using RMCE-Compatible F1 Hybrid Mouse Embryonic Stem Cells. <i>Stem Cell Reviews and Reports</i> , 2013, 9, 774-785.	5.6	37
53	The ROSA26-iPSC Mouse: A Conditional, Inducible, and Exchangeable Resource for Studying Cellular (De)Differentiation. <i>Cell Reports</i> , 2013, 3, 335-341.	6.4	35
54	Zeb2-Deficiency in the Adult Murine Hematopoietic Precursor Cells Leads to Differentiation Defects in Multiple Hematopoietic Lineages and a Myeloproliferative-Like Phenotype. <i>Blood</i> , 2012, 120, 1199-1199.	1.4	0

#	ARTICLE	IF	CITATIONS
55	The EMT regulator Zeb2/Sip1 is essential for murine embryonic hematopoietic stem/progenitor cell differentiation and mobilization. <i>Blood</i> , 2011, 117, 5620-5630.	1.4	94
56	Efficient mouse transgenesis using Gateway-compatible ROSA26 locus targeting vectors and F1 hybrid ES cells. <i>Nucleic Acids Research</i> , 2009, 37, e55-e55.	14.5	99